Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
“Our Phase 1/2 trial of relacorilant in combination with nab-paclitaxel has been productive,” said
Monday, June 3rd | |
Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA) P. Munster; S. Shepard |
Gastrointestinal (Noncolorectal) Cancer Poster Board: #235 Time: 8:00 - 11:00 am Location: Hall A |
Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models J. Veneris; G. Fleming |
Gynecologic Cancer Abstract No: e17039 |
About Relacorilant
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, one of the two receptors to which cortisol binds. Relacorilant does not bind to the body's other hormone receptors, including the progesterone receptor. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders. Current trials include a 180-patient, controlled Phase 2 trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer and a Phase 3 trial of relacorilant as monotherapy for patients with Cushing’s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents through 2037. Relacorilant has received orphan designation in
About
Corcept is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept’s approved product, Korlym®, was the first treatment approved by the
Abraxane® is a registered trademark of
CONTACT:
Director, Investor Relations
650-684-8725
cjames@corcept.com
www.corcept.com
Source: Corcept Therapeutics Incorporated